IDEXX Laboratories, Inc. $IDXX Shares Sold by Rathbones Group PLC

Rathbones Group PLC cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 137,219 shares of the company’s stock after selling 6,549 shares during the period. Rathbones Group PLC’s holdings in IDEXX Laboratories were worth $73,596,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Opal Wealth Advisors LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of IDEXX Laboratories by 55.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock worth $35,000 after buying an additional 30 shares during the period. Ameritas Advisory Services LLC acquired a new stake in IDEXX Laboratories in the second quarter valued at approximately $36,000. WPG Advisers LLC purchased a new position in IDEXX Laboratories in the first quarter worth approximately $37,000. Finally, Bank of Jackson Hole Trust lifted its stake in IDEXX Laboratories by 328.6% in the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock worth $39,000 after acquiring an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of analyst reports. BTIG Research raised their price objective on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. increased their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Jefferies Financial Group restated a “buy” rating and issued a $830.00 price target on shares of IDEXX Laboratories in a research note on Tuesday. Piper Sandler reaffirmed a “neutral” rating and set a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $730.50.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $708.45 on Friday. The company has a fifty day moving average of $645.28 and a two-hundred day moving average of $579.33. The company has a market capitalization of $56.57 billion, a PE ratio of 58.99, a P/E/G ratio of 4.06 and a beta of 1.62. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $735.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, November 3rd. The company reported $3.40 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.26. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the firm earned $2.80 earnings per share. The business’s revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Michael G. Erickson sold 406 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total transaction of $263,883.76. Following the transaction, the executive vice president directly owned 11,287 shares in the company, valued at approximately $7,336,098.52. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the transaction, the director directly owned 262 shares in the company, valued at $169,600.46. The trade was a 89.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,793 shares of company stock valued at $2,467,430 over the last quarter. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.